argenx initiates Phase II trial of ARGX-113 to treat pemphigus vulgaris
Belgium-based biotechnology firm argenx has initiated a Phase II clinical trial of its investigational agent, ARGX-113, to treat patients with pemphigus vulgaris (PV).
Authors: Gannon T Abstract Preview Several dermatoses are potentially fatal, and the mortality rate for some is quite high; prompt recognition and treatment are essential. Dr Gannon's succinct discussions of pemphigus vulgaris, necrotizing fasciitis, toxic epidermal necrolysis, Stevens-Johnson syndrome, toxic shock syndrome, and urticaria and angioedema will leave physicians well prepared to quickly identify these diseases and provide appropriate treatment. PMID: 29211550 [PubMed]
CONCLUSION: The dermatologic diseases studied frequently occur in the oral cavity. Among them, psoriasis was the most common dermatological disease, and LP frequently showed. CLINICAL SIGNIFICANCE: This study also depicts that diagnosis and management of these oral lesions should also be carried out by oral clinicians so as to improve the oral health functioning during the course of the disease. The intraoral examination should be incorporated to the routine of dermatologic assistance as the oral manifestations can represent preliminary signs or can coexist with the diseases. PMID: 29208790 [PubMed - in process]
Mycophenolate mofetil (MMF) is an immunosuppressive agent used in human and companion animal medicine for the treatment of immune-mediated disease. In humans, it was initially approved for prevention of renal allograft rejection and its use has since expanded to several other immune-mediated diseases. In companion animals it has been prescribed for the treatment of multiple immune-mediated conditions including, but not limited to, hemolytic anemia, acquired myasthenia gravis, and pemphigus vulgaris.
This study was performed to systematically summarize the results on the association of HLA-DQB1 polymorphisms with pemphigus vulgaris (PV) and other related factors. METHODS: A comprehensive literature search of PubMed, The Cochrane Library, Embase, and Google Scholar database was conducted to identify relevant articles in English, with the last report up to November 1, 2016. Heterogeneity test was performed, and publication bias was evaluated. Stata software 12.0 was used to perform the meta-analysis. Odds ratios (ORs) and 95% confidence intervals (CI) were used to describe the correlation by random-effects model. ...
Hematologic malignancies have been reported sporadically in patients with pemphigus.In the current study, significant associations were observed between pemphigus and chronic leukemia, multiple myeloma, and non-Hodgkin lymphoma.Further research is needed to confirm these findings in other cohorts.
Publication date: December 2017 Source:Actas Dermo-Sifiliográficas (English Edition), Volume 108, Issue 10 Author(s): A. Tirado-Sánchez, A. Bonifaz Paraneoplastic pemphigus (PNP), a subset of pemphigus, is a unique autoimmune blistering condition that can affect multiple organs other than the skin. It is a life-threatening disease associated with an underlying malignancy, most commonly of lymphoproliferative origin. The clinical picture may resemble pemphigus, pemphigoid, erythema multiforme, graft-versus-host disease, or lichen planus. The earliest and most consistent finding is a painful, severe, chronic a...
Plain language summary available online